In colon cancer cells (i.e., HT29 and HCT116), IFIT3 expression was downregulated under treatment with the anti-programmed cell death-1 (anti-PD-1) antibody nivolumab (Ierano et al. 2022). Here, IFIT3 is linked to colonic neoplasm.